Clinical trial · Observational
Breast Localization: RFID Tags vs Wire Localization
RFID Trial: Localization of Non-palpable Breast Lesions Using Radiofrequency Identification Tags or Wire
NCT04750889CI-TRIAL-00067253RFIDcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The RFID trial focuses on breast localization in patients with non-palpable breast cancers. It aims to demonstrate the improvement in patient comfort when using the Radio Frequency Identification (RFID) tag and LOCalizer™ device compared to the gold standard device.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasm Female | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RFID tags | Device | — | UNRESOLVED |
| Wire localization | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- RFID tags localization
- interventionNames
- Device: RFID tags
- label
- Wire localization
- interventionNames
- Device: Wire localization
Primary outcomes (1)
- measure
- Evaluation of the patients satisfaction
- timeFrame
- 1 years and 1 month
- description
- The value of the satisfaction score of the patient questionnaire from 0 (worst statisfaction) to 10 (better statisfaction)
Secondary outcomes (2)
- measure
- Satisfaction of surgeons and radiologists assessed by a questionnaire
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years of age or older, * Requiring conservative surgical management for a breast lesion -infra-clinical (fibroadenomas, papillomas, atypical lesions, neoplasia), whose histology will have been proven beforehand by anatomopathology. * Patients referred to mastology for preoperative identification by the surgeons * Able to give informed consent to participate in the research. * Affiliation to a Social Security regime Exclusion Criteria: * Multiple breast lesions * Patients with breast neoplasia during pregnancy. * Person deprived of liberty or under guardianship or incapable of giving consent * Refusal to participate
References
Publications (2)
- DERIVEDPete R, Pinard C, Sirodot F, Molnar I, Dressaire M, Ginzac A, Abrial C, Durando X, Tekath M. Patient satisfaction with radio-frequency identification (RFID) tag localization compared with wire localization for nonpalpable breast lesions: the RFID trial. BMC Cancer. 2025 Jan 22;25(1):123. doi: 10.1186/s12885-025-13453-0. PMID 39844175
- DERIVEDVeyssiere H, Dressaire M, Pete R, Pinard C, Molnar I, Abrial C, Ginzac A, Durando X, Tekath M. RFID trial: localization of non-palpable breast lesions using radiofrequency identification tags or wire. BMC Cancer. 2023 Jul 20;23(1):679. doi: 10.1186/s12885-023-11190-w. PMID 37468859